Navigation Links
SuperGen Reports Initiation of Multi-arm Phase 1b Trial of Novel Tyrosine Kinase Inhibitor
Date:12/17/2007

DUBLIN, Calif., December 17 /PRNewswire-FirstCall/ -- SuperGen, Inc. (Nasdaq: SUPG) today announced that investigators have dosed the first patient in a multi-arm Phase 1b clinical trial of MP470, a novel, oral, multi-targeted tyrosine kinase inhibitor (TKI). The trial will evaluate MP470 in combination with several standard of care chemotherapy regimens, including carboplatin/paclitaxel, carboplatin/etoposide, docetaxel, topotecan, and erlotinib. The trial is expected to enroll up to 105 patients at five study centers.

The Phase 1b trial is an open label, dose-escalation study designed to assess the safety and tolerability of MP470 in combination with these standard of care chemotherapy regimens, and to define the dose of MP470 to advance into Phase 2 combination studies. Additionally, the Company will assess pharmacokinetic and biomarker data from the study. The trial is open to chemotherapy nave or treatment experienced patients with a variety of solid tumors irrespective of previous lines of therapy.

"MP470 shows significant preclinical synergy with all of these well established chemotherapy agents. Its preclinical toxicology profile, as well as preliminary safety data from our ongoing Phase 1 trial suggests it will be safe to combine it with these regimens," said Dr. Gregory Berk, Chief Medical Officer of SuperGen. "In preclinical models, MP470 also suppresses Rad51, a protein that plays a key role in the mechanism of resistance to these treatments. We believe this offers the potential for MP470 to improve on the efficacy of these therapies. The multi-arm, Phase 1b design allows us to accelerate the clinical development of MP470 which will expedite the timeline to our Phase 2 program."

About MP470

MP470 is an oral, multi-targeted tyrosine kinase inhibitor that inhibits the mutant forms of c-KIT, PDGFR and FLT3, and suppresses c-MET and c-RET. MP470 also suppresses the Rad51 protein, a critical component of double- stranded DNA repair in cancer cells. Preclinical testing of MP470 has identified anti-tumor activity against a wide spectrum of cancers and is synergistic with a variety of chemotherapy agents as well as radiation therapy. MP470 is currently being evaluated in a single agent Phase 1 trial in patients with solid tumors.

About SuperGen

Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors, and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com

Forward-Looking Statements

This press release contains "forward-looking" statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and is subject to the safe harbor created thereby. The actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties. These forward-looking statements include statements regarding the ability of our products to enter clinical trials and the potential validation of our discovery process to produce new compounds. SuperGen's products may not enter clinical trials, and even if these products do enter clinical testing, there is no assurance that these tests will be successful. Additionally, the early successes in preclinical work may not be a validation of our discovery process and past success may not predict future success. Other factors that could cause actual results to differ materially from expectations include, but are not limited to, the risk factors detailed in the Company's filings with the Securities and Exchange Commission including reports on its most recently filed Form 10-K and Form 10-Q. These forward- looking statements are made only as of the date hereof, and we disclaim any obligation to update or revise the information contained in any such forward- looking statements, whether as a result of new information, future events or otherwise.

Contacts:

SuperGen

Timothy L. Enns

S.V.P., Corporate Communications& Business Development

(925) 560-0100

tenns@supergen.com

SuperGen

Mary M. Vegh

Manager, Investor Relations

(925) 560-2845

mary.vegh@supergen.com


'/>"/>
SOURCE SuperGen, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. SuperGens Novel Hypomethylating Agent Highlighted at AACR Plenary Session
2. Data Support use of SuperGens CLIMB Technology in Lead Development and Optimization
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Spherix Reports Second Quarter Earnings
5. Tapestry Reports Second Quarter 2007 Results
6. Callisto Reports on Second-Quarter 2007 Milestones
7. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
8. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
9. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
10. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
11. Biopure Reports on Meeting with the FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... Global and Chinese Surgical ... overview of the industry that covers definition, applications ... report explores into the international and Chinese players ... Surgical Mesh market spread across 150 pages providing ... is available at http://www.reportsnreports.com/reports/470569-global-and-chinese-surgical-mesh-industry-2016-market-research-report.html . ...
(Date:5/2/2016)... Kalorama Information noted the 5 Most Important ... a recent white paper.  The healthcare market research publisher ... growing market are among the top drivers of market ... EMR 2016: The Market for Electronic Medical Records ... of the EMR industry, and the report is consulted ...
(Date:5/2/2016)... , May 2, 2016  Deerfield announced ... financing of Graybug Vision, Inc. Graybug Vision is ... therapies that may transform care for ocular diseases ... Graybug Vision,s technology was first developed at Johns ... a startup venture. Graybug Vision ...
Breaking Medicine Technology:
(Date:5/3/2016)... Indianapolis, Ind. (PRWEB) , ... May 03, 2016 ... ... today that it has been selected by Tidelands Health, a three hospital system ... need to be constantly on the lookout for technology that enhances communication, drives ...
(Date:5/3/2016)... GA (PRWEB) , ... May 03, 2016 , ... Nationally recognized personal injury law firm ... Day weekend by giving free roses to anyone who wants one for their Mother or ... we recognize the important valuable contributions of Mothers.” Monge goes on to say, “we ...
(Date:5/3/2016)... Los Angeles, CA (PRWEB) , ... May 03, 2016 , ... ... Massage Chair with its user friendly Samsung tablet and exclusive Smart Application. The ... truly unbeatable massage. Starting each massage with a customized user profile and specialized massage ...
(Date:5/3/2016)... ... May 03, 2016 , ... For the sixth ... and Communication Technology (ICT) companies in the annual Branham300 listing. For 23 years, ... Canada, as ranked by revenue. , “We are honored to be on ...
(Date:5/3/2016)... ... May 03, 2016 , ... Huntington Beach orthopedic doctor , Dr. Rick ... can be used to diagnose and treat joint problems. During this procedure, Dr. Pospisil ... a special lighting system and lens that illuminate and magnify the various structures in ...
Breaking Medicine News(10 mins):